| abstract |
This invention relates to antibodies that specifically bind HER2 / neu, and in particular, chimeric 4D5 antibodies that bind to HER2 / neu, which have reduced glycosylation compared to known 4D5 antibodies. The invention also relates to methods for using 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders and infectious diseases. |